SkinBioTherapeutics PLC

Market Cap:
£25.53 m
16.38 GBX
52 weeks high
52 weeks low

In brief

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain at The University of Manchester.

The SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.

SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.

Deep dive We explore the investor case for growth companies


  • Spun out from OptiBiotix in 2017
  • Harnesses good bacteria to improve and support skin
  • Partnerships with Croda and Winclove

Insight Widest with the analysis, Proactive gives perspectives that others don't.